Retrospective analysis of albumin-bound paclitaxel in the treatment of elderly patients with advanced non-small cell lung cancer
10.3760/cma.j.issn.0253-3766.2016.08.009
- VernacularTitle:白蛋白结合型紫杉醇治疗老年晚期非小细胞肺癌的临床评估
- Author:
Puyuan XING
1
;
Xuezhi HAO
;
Yan WANG
;
Xingsheng HU
;
Junling LI
Author Information
1. 100021,国家癌症中心 北京协和医学院中国医学科学院肿瘤医院内科
- Keywords:
Carcinoma,non-small-cell lung;
Drug therapy;
Treatment outcome;
Albumin-bound paclitaxel
- From:
Chinese Journal of Oncology
2016;38(8):615-619
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the safety and short?term efficacy of sigle drug albumin?bound paclitaxel (ABP) in the treatment of elderly patients with advanced non?small cell lung cancer (NSCLC). Methods A total of 23 elderly patients with advanced NSCLC who received weekly ABP regimen (130 mg/m2/week) in our hospital from October 2011 to March 2014 were retrospectively evaluated. The short?term efficacy, progression?free survival ( PFS) , and overall survival ( OS) were analyzed. Results The median treatment period was 4 cycles (2?10 cycles). Partial response, stable disease, progressive disease, overall response rate, and disease control rate were 26.1%, 43.5%, 30.4%, 26.1% and 69.6%, respectively. The median PFS was 5.33 months (95% CI:2.95?7.70 months), while the median OS was 40.33 months (95% CI:29.82?50.83 months). Major adverse events included leucopenia (82.6%), neutropenia (78.3%), nausea or vomiting (56.5%), fatigue (52.2%), peripheral neuropathy (26.1%), myalgia/arthralgia (30.4%), thrombocytopenia ( 13. 0%) and arrhythmia ( 4. 3%) . The patients accompanied with chronic diseases had significantly higher incidence rate of peripheral neuropathy and myalgia/arthralgia compared with the patients without accompanied chronic diseases ( 50. 0% vs. 9. 1% and 66. 7% vs. 9. 1%, P<0. 05 for both ) . Conclusion The weekly single drug ABP regimen is effective and well?tolerated in elderly patients with advanced NSCLC.
